Omeros (NASDAQ:OMER) Posts Earnings Results, Beats Estimates By $0.29 EPS

Posted by Brenda Bartman on Aug 13th, 2026

Omeros (NASDAQ:OMER – Get Free Report) released its quarterly earnings results on Wednesday. The biopharmaceutical company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.27) by $0.29, FiscalAI reports. The company had revenue of $28.53 million during the quarter, compared to the consensus estimate of $12.69 million.

Here are the key takeaways from Omeros’ conference call:

YARTEMLEA generated $32.2 million in gross sales and $28.5 million in net sales in its first full quarter, with net sales up 188% sequentially. Adoption expanded to 73 transplant-center accounts, and adult patients represented approximately 75% of sales.
Reimbursement support strengthened as YARTEMLEA received a permanent CMS J-code and an approved NTAP of up to $287,000 per inpatient treatment course, effective October 1. The company also generated $4.1 million in positive operating cash flow and expects to remain on track for company-wide cash-flow positivity by mid-2027.
Omeros reduced its 2029 convertible-note principal by 43% to $40.3 million, lowering future interest expense and potential dilution by approximately 5.8 million shares year to date.
The European Medicines Agency’s CHMP issued a negative opinion on YARTEMLEA’s TA-TMA application; Omeros has requested re-examination. The company is not providing revenue guidance and expects higher third-quarter operating expenses from continued commercial investment and increased OMS805 development spending.

Omeros Price Performance

Shares of OMER stock traded up $3.64 on Thursday, hitting $17.35. The stock had a trading volume of 13,392,900 shares, compared to its average volume of 1,679,764. The company’s 50 day moving average price is $10.60 and its 200-day moving average price is $11.47. Omeros has a 1 year low of $3.94 and a 1 year high of $18.14. The firm has a market capitalization of $1.26 billion, a P/E ratio of 24.79 and a beta of 2.54.

More Omeros News

Here are the key news stories impacting Omeros this week:

Positive Sentiment: Omeros exceeded second-quarter expectations. The biopharmaceutical company reported earnings of $0.02 per share, versus analyst expectations for a $0.27 loss, while revenue reached $28.53 million compared with the $12.69 million consensus estimate. The result also improved from a $0.53-per-share loss a year earlier. Omeros Q2 Earnings and Revenues Beat Estimates
Positive Sentiment: YARTEMLEA sales momentum supported the outlook. Management highlighted strong commercial momentum for YARTEMLEA, alongside debt reduction and share-buyback activity, factors that helped drive the after-hours and subsequent rise in OMER shares. OMER Stock Soars After YARTEMLEA Sales Momentum, Debt Reduction and Share Buybacks
Positive Sentiment: H.C. Wainwright maintained a Buy rating and $33 price target. Analyst Brandon Folkes cited the strong YARTEMLEA launch and reduced C5 competition as reasons to retain the bullish view, implying substantial potential upside relative to recent trading levels. Omeros Buy Rating and $33 Price Target
Neutral Sentiment: Options activity surged. Traders purchased 12,612 call options, about 235% above average daily call volume. This indicates heightened bullish speculation, but does not necessarily represent long-term institutional conviction.
Neutral Sentiment: Reported short-interest data showed zero shares sold short, making the figures unusable for assessing short-covering pressure or a potential short squeeze.

Insider Activity at Omeros

In other Omeros news, Director Thomas J. Cable sold 7,500 shares of the business’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $11.61, for a total value of $87,075.00. Following the transaction, the director directly owned 35,067 shares of the company’s stock, valued at approximately $407,127.87. The trade was a 17.62% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Omeros

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Abel Hall LLC purchased a new position in Omeros in the fourth quarter valued at about $176,000. Osaic Holdings Inc. boosted its position in shares of Omeros by 34.6% in the fourth quarter. Osaic Holdings Inc. now owns 7,547 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 1,938 shares during the period. Arax Advisory Partners grew its stake in shares of Omeros by 56.4% in the fourth quarter. Arax Advisory Partners now owns 5,255 shares of the biopharmaceutical company’s stock valued at $90,000 after buying an additional 1,894 shares in the last quarter. Rafferty Asset Management LLC acquired a new stake in shares of Omeros in the fourth quarter valued at about $210,000. Finally, Bridgeway Capital Management LLC grew its holdings in Omeros by 78.8% during the 3rd quarter. Bridgeway Capital Management LLC now owns 56,715 shares of the biopharmaceutical company’s stock valued at $233,000 after purchasing an additional 25,000 shares in the last quarter. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. D. Boral Capital reiterated a “buy” rating and set a $36.00 price objective on shares of Omeros in a research note on Tuesday, April 21st. HC Wainwright reaffirmed a “buy” rating on shares of Omeros in a report on Monday, July 27th. Zacks Research cut Omeros from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Weiss Ratings raised Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. Finally, Wall Street Zen lowered Omeros from a “buy” rating to a “hold” rating in a research report on Sunday, June 7th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, Omeros presently has an average rating of “Moderate Buy” and an average price target of $38.00.

View Our Latest Research Report on Omeros

About Omeros

(Get Free Report)

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.